Literature DB >> 23492918

Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study.

Emmilia A Dowlatshahi1, Maryam Kavousi2, Tamar Nijsten3, M Arfan Ikram4, Albert Hofman2, Oscar H Franco2, Marlies Wakkee1.   

Abstract

Psoriasis has been suggested to be an independent risk factor for cardiovascular disease (CVD); however, available studies have shown inconsistent results. In this study, embedded within the population-based Rotterdam Study, we aimed to assess the association between psoriasis and cardiovascular outcomes. Adjusted means were calculated for subclinical atherosclerosis using general linear models. Using Cox regression, the hazards of cardiovascular events for psoriasis, as a time-dependent variable, were calculated. A total of 262 psoriasis (24% systemic/UV treatment) and 8,009 reference subjects were followed up for a mean of 11 years. Psoriasis patients were significantly younger, smoked more, and had higher diastolic blood pressure and body mass index levels. The adjusted carotid intima-media thickness was 1.02±0.18 mm for psoriasis and 1.02±0.16 mm for reference subjects. Similarly, crude and adjusted ankle-brachial index, pulse-wave velocity, and coronary artery calcium scores did not differ between the two groups. The risk of incident CVD was not increased in psoriasis (adjusted hazard ratio 0.73, 95% confidence interval 0.50-1.06). The results were similar when coronary heart disease, stroke, and heart failure were analyzed separately. Psoriasis patients with predominantly mild disease from the general population are as likely to develop atherosclerosis and cardiovascular events as subjects without psoriasis.

Entities:  

Mesh:

Year:  2013        PMID: 23492918     DOI: 10.1038/jid.2013.131

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  34 in total

1.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

2.  The Rotterdam Study: 2014 objectives and design update.

Authors:  Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2013-11-21       Impact factor: 8.082

3.  Assessment of arterial stiffness and cardiovascular hemodynamics by oscillometric method in psoriasis patients with normal cardiac functions.

Authors:  Murat Sunbul; Dilek Seckin; Erdal Durmus; Zuleyha Ozgen; Mehmet Bozbay; Ayfer Bozbay; Tarik Kivrak; Mustafa Oguz; Ibrahim Sari; Tulin Ergun; Mehmet Agirbasli
Journal:  Heart Vessels       Date:  2014-03-15       Impact factor: 2.037

4.  Multivariable analysis.

Authors:  Marlies Wakkee; Loes M Hollestein; Tamar Nijsten
Journal:  J Invest Dermatol       Date:  2014-05       Impact factor: 8.551

5.  The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events.

Authors:  Alexander Egeberg; Lone Skov; Aditya A Joshi; Lotus Mallbris; Gunnar H Gislason; Jashin J Wu; Justin Rodante; Joseph B Lerman; Mark A Ahlman; Joel M Gelfand; Nehal N Mehta
Journal:  J Am Acad Dermatol       Date:  2017-08-18       Impact factor: 11.527

6.  The Rotterdam Study: 2018 update on objectives, design and main results.

Authors:  M Arfan Ikram; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Albert Hofman
Journal:  Eur J Epidemiol       Date:  2017-10-24       Impact factor: 8.082

7.  Psoriasis is an independent predictor of increased risk of allergic reaction during percutaneous coronary interventions. Big data analysis from the Polish National PCI Registry (ORPKI).

Authors:  Zbigniew Siudak; Kalina Wysocka-Dubielecka; Krzysztof Malinowski; Artur Dziewierz; Tomasz Tokarek; Krzysztof Plens; Dariusz Dudek
Journal:  Cardiol J       Date:  2018-08-29       Impact factor: 2.737

8.  Evaluation of subclinical atherosclerosis in Egyptian psoriatic patients.

Authors:  Raghda Ghonimy Elsheikh; Tarek El-Sayed Amin; Amal Ahmad El-Ashmawy; Samah Ibrahim Abd El-Fttah Abdalla
Journal:  J Saudi Heart Assoc       Date:  2013-12-18

Review 9.  Does treatment of psoriasis reduce the risk of cardiovascular disease?

Authors:  Sarah Churton; Liza Brown; Thuzar M Shin; Neil J Korman
Journal:  Drugs       Date:  2014-02       Impact factor: 9.546

Review 10.  Psoriasis.

Authors:  Paola Di Meglio; Federica Villanova; Frank O Nestle
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.